Clinical trials
Terminated Phase 2 Carcinoma, Non-Small-Cell Lung trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
293 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 3 |
| 2002 | 2 |
| 2003 | 6 |
| 2004 | 7 |
| 2005 | 16 |
| 2006 | 23 |
| 2007 | 21 |
| 2008 | 19 |
| 2009 | 13 |
| 2010 | 12 |
| 2011 | 9 |
| 2012 | 8 |
| 2013 | 8 |
| 2014 | 15 |
| 2015 | 17 |
| 2016 | 10 |
| 2017 | 11 |
| 2018 | 19 |
| 2019 | 15 |
| 2020 | 13 |
| 2021 | 16 |
| 2022 | 13 |
| 2023 | 8 |
| 2024 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 293 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 12 |
| M.D. Anderson Cancer Center | 8 |
| Merck Sharp & Dohme LLC | 8 |
| Novartis Pharmaceuticals | 7 |
| Bristol-Myers Squibb | 6 |
| Duke University | 6 |
| GlaxoSmithKline | 5 |
| Eli Lilly and Company | 4 |
| Hellenic Oncology Research Group | 4 |
| Hoffmann-La Roche | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 293 |
| Lung Neoplasms | 67 |
| Neoplasm Metastasis | 22 |
| Adenocarcinoma of Lung | 17 |
| Melanoma | 12 |
| Brain Neoplasms | 10 |
| Small Cell Lung Carcinoma | 10 |
| Neoplasms | 9 |
| Carcinoma, Renal Cell | 8 |
| Adenocarcinoma | 7 |
Trials
Showing 1 to 25 of 293. Each trial links to its page on Pharma Observatory.
193 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.